GPnotebook flags the placebo-controlled trial, whose researchers report that continuing the maximum tolerated dose held both weight loss and health gains.
Recap by typeshit. Post by GPnotebook on X.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
13:47
Ketcham runs through the habits she credits for her 90 pound loss on tirzepatide. Her personal take, not medical advice, so check with a doctor.
9:07
The endocrinologist takes on whether people can get retatrutide now, setting gray market supply against the results from Lilly's actual trials.
Loading…